Poseida Therapeutics (NASDAQ:PSTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note issued to investors on Monday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Poseida Therapeutics Price Performance

Shares of NASDAQ PSTX opened at $2.16 on Monday. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $207.94 million, a price-to-earnings ratio of -1.55 and a beta of 0.36. Poseida Therapeutics has a twelve month low of $1.54 and a twelve month high of $4.27. The business has a 50 day simple moving average of $3.16 and a 200-day simple moving average of $2.94.

Poseida Therapeutics (NASDAQ:PSTX) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 190.76% and a negative return on equity of 94.90%. The firm had revenue of $25.00 million during the quarter, compared to the consensus estimate of $12.50 million. As a group, equities research analysts expect that Poseida Therapeutics will post -1.77 earnings per share for the current year.

Institutional Investors Weigh In On Poseida Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Silverarc Capital Management LLC boosted its stake in Poseida Therapeutics by 21.1% in the third quarter. Silverarc Capital Management LLC now owns 3,567,985 shares of the company’s stock valued at $8,492,000 after acquiring an additional 622,037 shares during the period. Blair William & Co. IL boosted its position in Poseida Therapeutics by 30.2% during the 3rd quarter. Blair William & Co. IL now owns 740,650 shares of the company’s stock valued at $1,763,000 after purchasing an additional 171,910 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in Poseida Therapeutics by 186.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,857 shares of the company’s stock worth $816,000 after buying an additional 223,280 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Poseida Therapeutics by 10.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 259,929 shares of the company’s stock worth $619,000 after buying an additional 23,960 shares during the period. Finally, MCF Advisors LLC lifted its stake in Poseida Therapeutics by 476.4% in the fourth quarter. MCF Advisors LLC now owns 247,024 shares of the company’s stock valued at $830,000 after buying an additional 204,170 shares during the last quarter. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.